25

100

180

130

Complete if Known Effective on 12/08/2004. ant to the Consolidated Appropriations Act, 2005 (H.R. 4818). **Application Number** 10/759.762 FEE TRANSMITTAL January 16, 2004 Filing Date For FY 2005 First Named Inventor Tsien, Roger Y. T. Solola **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 Art Unit 1626 TOTAL AMOUNT OF PAYMENT (\$) 13002307E-152810US Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check Credit Card Money Order None Other (please identify): Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 Credit any overpayments WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038 **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **SEARCH FEES FILING FEES EXAMINATION FEES Small Entity Small Entity Small Entity** Fees Paid (\$) Application Type Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) Utility 300 150 500 250 200 100 Design 200 100 100 50 130 65 Plant 200 100 300 150 160 80 Reissue 300 150 500 250 600 300 0 0 Ő Provisional 200 100 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent 50 Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 200 Multiple dependent claims **Total Claims Extra Claims** Fee Paid (\$) Fee (\$) Multiple Dependent Claims -20 or HP = Fee Paid (\$) Fee (\$) HP = highest number of total claims paid for, if greater than 20 Indep. Claims Extra Claims Fee (\$) Fee Paid (\$) -3 or HP = HP = highest number of independent claims paid for, if greater than 3 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Number of each additional 50 or fraction thereof Fee (\$) Extra Sheets Fee Paid (\$) (round up to a whole number) x _ - 100 = _____ / 50 = 4. OTHER FEE(S) Fees Paid (\$)

SUBMITTED BY			
Signature	Senneth - lew	Registration No. (Attorney/Agent) 51,846	Telephone 858-350-6100
Name (Print/Type)	Kenneth E. Jenkine, Fn.D.		Date August 10, 2005

Non-English Specification, \$130 fee (no small entity discount)

Other: Terminal Disclaimer

AUG 1 2 2005



TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING SECOND APPLICATION

Docket Number (Optional) 02307E-152810US

In re Application of: Roger Y. Tsien

Application No.: 10/759,762

Filed: 01/16/2004

For: SYNTHETIC MOLECULES FOR LABELING HISTIDINE-RICH PROTEINS

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent: granted on the pending **reference** application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. Solution For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2.	The undersigned is an attorney or agent of record.	Reg. No. 51,846.

Juda S Stevenson Signature

July 20, 2005

Date

Linda S Stevenson

Typed or printed name

510-587-6000

Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

60539201 v1

08/12/2005 HVUONG1 00000068 201430 10759762

01 FC:1814

130.00 DA



STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Roger Y. Tsien, et al.						
Application No./Patent No.: 10/759,762 Filed/Issue Date: January 16, 2004						
Entitled: SYNTHETIC MOLECULES FOR LABELING HISTIDI	INE-RICH PROTEINS					
The Regents of the University of California , a non-processing (Name of Assignee) , The Regents of the University of California , a non-processing (Type of Assignee)	rofit organization signee, e.g., corporation, partnership, university, government agency, etc.)					
states that it is: 1.						
2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is%						
in the patent application/patent identified above by virtue of either:						
 An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached. OR B. \(\int \) A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown 						
below: 1. From: <u>Howard Hughes Medical Institute</u> T The document was recorded in the United States P Reel <u>015551</u> , Frame <u>0991</u> ,	Patent and Trademark Office at					
2. From: <u>Hauser, Christina</u> The document was recorded in the United States P Reel <u>015551</u> , Frame <u>0936</u> ,	To :The Regents of the University of California Patent and Trademark Office at					
3. From: 1	Го :					
The document was recorded in the United States P Reel, Frame						
Additional documents in the chain of title are listed on a supplemental sheet.						
Copies of assignments or other documents in the chain of titl [NOTE: A separate copy (i.e., a true copy of the original assi Division in accordance with 37 CFR Part 3, if the assignment MPEP 302.8]	gnment document(s)) must be submitted to Assignment					
The undersigned (whose title is supplied below) is authorized to a	act on behalf of the assignee. July 20, 2005					
Signature						
Linda S. Stevenson	510-587-6000					
Printed or Typed Name	Telephone Number					
Patent Prosecution Manager						
Title ,						